Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 6/20 | 0.40 |
| ▸ | PYGM | P11217 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878893 | 1.00 | GAA (0.45) | GAAEPHX2PYGLPYGMNFKB1 | |
| SCHEMBL4072157 | 0.91 | EPHX2 (0.46) | GAAEPHX2PYGLPYGMNFKB1 | |
| SCHEMBL13878889 | 0.91 | EPHX2 (0.46) | GAAEPHX2PYGLPYGMNFKB1 | |
| SCHEMBL653581 | 0.86 | GAA (0.45) | GAAEPHX2PYGLPYGMNFKB1 | |
| SCHEMBL5133011 | 0.86 | GAA (0.45) | GAAEPHX2PYGLPYGMNFKB1 | |
| SCHEMBL653580 | 0.86 | GAA (0.45) | GAAEPHX2PYGLPYGMNFKB1 | |
| SCHEMBL30767932 | 0.86 | GAA (0.45) | GAAEPHX2PYGLPYGMNFKB1 | |
| SCHEMBL8210416 | 0.84 | EPHX2 (0.47) | GAAEPHX2NFKB1NFKB2RELA | |
| SCHEMBL6177311 | 0.84 | EPHX2 (0.47) | GAAEPHX2NFKB1NFKB2RELA | |
| SCHEMBL29270789 | 0.83 | GAA (0.43) | GAAEPHX2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1819332-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LTD (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1819332-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | Prosidion Limited (GB) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006059164-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PC, GOT2, PDK1 | GAA 734/4885EPHX2 1684/4885PYGL 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.